Emrusolmin

Emrusolmin
Clinical data
Other names	Anle138b, TEV-56286
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 5-(1,3-benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole;
CAS Number	882697-00-9;
PubChem CID	44608289;
DrugBank	DB13927;
ChemSpider	58825097;
UNII	E7WRA77JET;
KEGG	D80685;
ChEBI	CHEBI:232606;
ChEMBL	ChEMBL4748063;
Chemical and physical data
Formula	C16H11BrN2O2
Molar mass	343.180 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1OC2=C(O1)C=C(C=C2)C3=CC(=NN3)C4=CC(=CC=C4)Br;
	InChI InChI=InChI=1S/C16H11BrN2O2/c17-12-3-1-2-10(6-12)13-8-14(19-18-13)11-4-5-15-16(7-11)21-9-20-15/h1-8H,9H2,(H,18,19); Key:RCQIIBJSUWYYFU-UHFFFAOYSA-N;

Emrusolmin (development code Anle138b) is an experimental drug for the treatment of neurodegenerative diseases. It is an inhibitor of protein aggregation, particularly preventing the aggregation of α-synuclein which is implicated in the development of Parkinson's disease. Other proteins it inhibits the aggregation of include tau which is associated with Alzheimer's disease (AD) and tauopathy, and amyloid beta which is associated with AD.

It is currently in clinical trials for Parkinson's disease and multiple system atrophy.